Achieve Life Sciences Appoints Three Senior Executives
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: Newsfilter
- Executive Appointments: Achieve Life Sciences has appointed Christopher Martin to its Board of Directors, Mark Zappia as Senior Vice President of Commercial, and Jim Willis as Vice President of Sales, all of whom bring successful commercial experience from Verona Pharma, which is expected to drive the company towards commercialization.
- Financing Context: These appointments come on the heels of Achieve securing up to $354 million in financing, including $180 million upfront and up to $174 million from milestone-based warrants tied to FDA approval, demonstrating the company's commitment to advancing cytisinicline's commercialization.
- Market Potential: Cytisinicline could become the first new smoking cessation therapy in over two decades and the first ever for vaping cessation, addressing the urgent needs of approximately 25 million smokers and 18 million e-cigarette users in the U.S., indicating significant market potential.
- Leadership Confidence: New CEO Andrew D. Goldberg stated that the addition of these executives is one of the most consequential decisions of his tenure, reflecting Achieve's strategic positioning to tackle public health issues and enhancing confidence in the company's future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHV
Wall Street analysts forecast ACHV stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.530
Low
12.00
Averages
15.50
High
19.00
Current: 6.530
Low
12.00
Averages
15.50
High
19.00
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Achieve Life Sciences Shares Rise 10% Despite FDA Complete Response Letter
- FDA Response Letter: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its smoking cessation drug cytisinicline; however, shares rose approximately 10%, indicating market confidence in the company's future potential.
- Manufacturing Issues: The FDA highlighted remaining manufacturing-related issues at a third-party site and incomplete product labeling by the action date, which could impact future production and market entry timelines.
- No Safety Concerns: Importantly, the FDA did not raise any efficacy or safety concerns regarding cytisinicline, providing a solid foundation for the company's ongoing product development and market strategy.
- Clear Future Plans: Achieve Life Sciences aims to resubmit its New Drug Application in Q4 2026 and expects to launch the product in H1 2027, supported by $180 million in financing, demonstrating a proactive approach to future market opportunities.
See More
Achieve Life Sciences Receives FDA Complete Response Letter
- FDA Response: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its Cytisinicline New Drug Application, citing deficiencies in Good Manufacturing Practices at a third-party facility and incomplete product labeling, although clinical efficacy and safety were not questioned.
- Manufacturing Partnership: In anticipation of the FDA's OAI classification, Achieve partnered with U.S.-based Adare Pharma Solutions, successfully transferring analytical testing methods and manufacturing its first engineering batch at the Adare facility, ensuring all testing procedures are qualified.
- Future Plans: The company plans to resubmit its NDA in Q4 2026, naming Adare as its primary manufacturing partner, and if the resubmitted NDA is accepted and reviewed without major deficiencies, Cytisinicline could receive FDA approval in H1 2027.
- Market Reaction: Despite the challenges, ACHV is currently trading at $5.41, reflecting an 11.55% increase, indicating market optimism regarding the potential for future approval.
See More
Achieve Life Sciences Receives Complete Response Letter from FDA
- FDA Feedback: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, citing deficiencies at a third-party manufacturing facility while identifying no clinical efficacy or safety issues, indicating the need for further improvements in product quality to meet regulatory standards.
- Manufacturing Partner Change: The company has partnered with Adare Pharma Solutions as its new commercial manufacturing partner and has successfully completed the technology transfer and first engineering batch production, aiming to address the manufacturing issues raised by the FDA and expedite future product launch processes.
- Clinical Trial Support: The NDA for cytisinicline is supported by clinical trial data involving over 1,500 participants, including two successful Phase 3 trials demonstrating significant smoking cessation effects, providing strong backing for the company's future FDA review despite current manufacturing challenges.
- Market Potential: With approximately 25 million adults in the U.S. smoking and a lack of FDA-approved treatments for e-cigarette cessation, the development of cytisinicline not only addresses this market need but also has the potential for commercialization in the first half of 2027, further solidifying the company's position in the tobacco alternatives market.
See More
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline
- Long-Term Safety Study: Achieve Life Sciences presented long-term safety data for Cytisinicline at the American Thoracic Society 2026 Annual Meeting, with 52-week findings indicating good tolerability in adults with nicotine dependence, potentially paving the way for future regulatory approvals.
- FDA Review Progress: The FDA has set a PDUFA date of June 20, 2026, for Cytisinicline's New Drug Application, marking a significant advancement in the company's efforts to bring the drug to market, which is likely to attract increased investor interest.
- Clinical Trial Participant Data: The ORCA-OL trial enrolled 475 smokers, with 84.6% being cigarette smokers and 12.8% e-cigarette users, demonstrating Cytisinicline's broad applicability across different smoking populations, which may enhance market acceptance.
- Adverse Event Monitoring: While 66.3% of participants reported treatment-related adverse events, most were deemed unrelated to Cytisinicline, and 94.8% of these events were mild or moderate, indicating the drug's safety and potentially boosting physician confidence in prescribing it.
See More
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline
- Clinical Data Completeness: Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at the American Thoracic Society 2026 Annual Meeting, reinforcing the foundation for its New Drug Application (NDA) and future market access.
- Safety Analysis Results: Among 475 participants, only 2.5% reported nausea during 52 weeks of continuous exposure, indicating good tolerability of the treatment, with 94.8% of adverse events classified as mild or moderate, demonstrating the drug's safety across a diverse population.
- Market Demand Opportunity: With approximately 25 million adults smoking in the U.S. and no FDA-approved treatments for e-cigarette cessation, the development of Cytisinicline addresses this critical market gap, expected to meet the rising demand for smoking cessation solutions.
- Regulatory Progress: Achieve has submitted its NDA to the FDA, with a review date set for June 20, 2026; as clinical evidence solidifies, the company is poised to potentially launch this much-needed treatment option, further driving business growth.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Achieve Life Sciences Shares Rise 10% Despite FDA Complete Response Letter
- FDA Response Letter: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its smoking cessation drug cytisinicline; however, shares rose approximately 10%, indicating market confidence in the company's future potential.
- Manufacturing Issues: The FDA highlighted remaining manufacturing-related issues at a third-party site and incomplete product labeling by the action date, which could impact future production and market entry timelines.
- No Safety Concerns: Importantly, the FDA did not raise any efficacy or safety concerns regarding cytisinicline, providing a solid foundation for the company's ongoing product development and market strategy.
- Clear Future Plans: Achieve Life Sciences aims to resubmit its New Drug Application in Q4 2026 and expects to launch the product in H1 2027, supported by $180 million in financing, demonstrating a proactive approach to future market opportunities.
See More
Achieve Life Sciences Receives FDA Complete Response Letter
- FDA Response: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its Cytisinicline New Drug Application, citing deficiencies in Good Manufacturing Practices at a third-party facility and incomplete product labeling, although clinical efficacy and safety were not questioned.
- Manufacturing Partnership: In anticipation of the FDA's OAI classification, Achieve partnered with U.S.-based Adare Pharma Solutions, successfully transferring analytical testing methods and manufacturing its first engineering batch at the Adare facility, ensuring all testing procedures are qualified.
- Future Plans: The company plans to resubmit its NDA in Q4 2026, naming Adare as its primary manufacturing partner, and if the resubmitted NDA is accepted and reviewed without major deficiencies, Cytisinicline could receive FDA approval in H1 2027.
- Market Reaction: Despite the challenges, ACHV is currently trading at $5.41, reflecting an 11.55% increase, indicating market optimism regarding the potential for future approval.
See More
Achieve Life Sciences Receives Complete Response Letter from FDA
- FDA Feedback: Achieve Life Sciences received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, citing deficiencies at a third-party manufacturing facility while identifying no clinical efficacy or safety issues, indicating the need for further improvements in product quality to meet regulatory standards.
- Manufacturing Partner Change: The company has partnered with Adare Pharma Solutions as its new commercial manufacturing partner and has successfully completed the technology transfer and first engineering batch production, aiming to address the manufacturing issues raised by the FDA and expedite future product launch processes.
- Clinical Trial Support: The NDA for cytisinicline is supported by clinical trial data involving over 1,500 participants, including two successful Phase 3 trials demonstrating significant smoking cessation effects, providing strong backing for the company's future FDA review despite current manufacturing challenges.
- Market Potential: With approximately 25 million adults in the U.S. smoking and a lack of FDA-approved treatments for e-cigarette cessation, the development of cytisinicline not only addresses this market need but also has the potential for commercialization in the first half of 2027, further solidifying the company's position in the tobacco alternatives market.
See More
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline
- Long-Term Safety Study: Achieve Life Sciences presented long-term safety data for Cytisinicline at the American Thoracic Society 2026 Annual Meeting, with 52-week findings indicating good tolerability in adults with nicotine dependence, potentially paving the way for future regulatory approvals.
- FDA Review Progress: The FDA has set a PDUFA date of June 20, 2026, for Cytisinicline's New Drug Application, marking a significant advancement in the company's efforts to bring the drug to market, which is likely to attract increased investor interest.
- Clinical Trial Participant Data: The ORCA-OL trial enrolled 475 smokers, with 84.6% being cigarette smokers and 12.8% e-cigarette users, demonstrating Cytisinicline's broad applicability across different smoking populations, which may enhance market acceptance.
- Adverse Event Monitoring: While 66.3% of participants reported treatment-related adverse events, most were deemed unrelated to Cytisinicline, and 94.8% of these events were mild or moderate, indicating the drug's safety and potentially boosting physician confidence in prescribing it.
See More
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline
- Clinical Data Completeness: Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at the American Thoracic Society 2026 Annual Meeting, reinforcing the foundation for its New Drug Application (NDA) and future market access.
- Safety Analysis Results: Among 475 participants, only 2.5% reported nausea during 52 weeks of continuous exposure, indicating good tolerability of the treatment, with 94.8% of adverse events classified as mild or moderate, demonstrating the drug's safety across a diverse population.
- Market Demand Opportunity: With approximately 25 million adults smoking in the U.S. and no FDA-approved treatments for e-cigarette cessation, the development of Cytisinicline addresses this critical market gap, expected to meet the rising demand for smoking cessation solutions.
- Regulatory Progress: Achieve has submitted its NDA to the FDA, with a review date set for June 20, 2026; as clinical evidence solidifies, the company is poised to potentially launch this much-needed treatment option, further driving business growth.
See More
